Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIXADI on a Mobile Pharmacy Clinic for OUD
NCT07176351Phase 4Recruiting
- Sponsor
- Yale University
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of buprenorphine extended-release injection in opioid use disorder (OUD), sponsored by Yale University. Primary endpoint: Retention of XR-B at 6 months. Started Sep 2026; status: recruiting.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07176351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176351.